logo
Sign in

INTRA-CELLULAR THERAPIES, INC.

NEW YORK, NY · Founded 2012 · Biotech · Acquired

Digital fluorescence imaging and photometric microscope instruments for research

Claim this profile

Follows are private to you and power your alerts

Updated · intracellular.com

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2012
Latest Form D
$70.3M, Sep 2013
Total capital
$71.5M
Federal grants
$348K
1 award · 2016
Rank in peer group#420 of 502
Private capital raised
$70.3M
1 Form D · last Sep 2013
158 months since last filing
Federal contracts
$849K
1 award · Defense
Rank in Biotech#197 of 4373
Granted patents
19
21 pending · first 2025
Rank in peer group#1 of 502

Capital timeline

200520072009201120132015FEDERAL ↑EQUITY ↓Cumulative $71.5M$849K$348K1st Form D$70.3M
200520072009201120132015FEDERAL ↑EQUITY ↓Cumulative $71.5M$849K$348K1st Form D$70.3M

Latest events

  • Federal grantHealth and Human S · Phase I · Development of PDE2 Inhibitors for Treatment of Anxiety/Depression in Autism/Schizophrenia$348K
  • Private capital raisedForm D · SEC · 1st filing$70.3M
  • Federal contractDefense · 200607!601292!2100!W81XWH!US Army Medical Research Acq ACT!W81XWH06C0013 !a!n! !n! ! !20051104!20060609!112765909!112765909!112765909!N!INTRA-CELLULAR Therapies, Inc !3960 Broadway !new York !NY!10032!29225!021!24!FORT Detrick !frederick !maryland !+000000069438!N!N!000000119438!AA13!RDTE/AGR-INSECT & Disease Cntl-adv Tech Dev !S1 !services !000 !* !541380!A!A!3! ! ! ! ! !999$849K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

94months

from INTRA-CELLULAR THERAPIES, INC.’s first federal award to its first private round.

First federal award · Nov 2005
Defense · $849K
First Form D · Sep 2013
$70.3M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#1 · top 1%
  • Linked publications#5 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Allen FienbergDirectorNamed in SEC Form D filings
  • Christopher AlafiDirectorNamed in SEC Form D filings
  • David J. KipnisDirectorNamed in SEC Form D filings
  • Joel J. MarcusDirectorNamed in SEC Form D filings
  • Kimberly VanoverExecutive OfficerNamed in SEC Form D filings
  • Lawrence J. HinelineExecutive OfficerNamed in SEC Form D filings
Show all 12 people
  • Lawrence WennogleExecutive OfficerNamed in SEC Form D filings
  • Michael RawlinsDirectorNamed in SEC Form D filings
  • Richard J. LernerDirectorNamed in SEC Form D filings
  • Samir NasriDirectorNamed in SEC Form D filings
  • Sharon MatesExecutive Officer, DirectorNamed in SEC Form D filings
  • Sir Michael J. RawlinsDirectorNamed in SEC Form D filings

What it has protected

USPTO · 19 granted of 40
  • PendingNovel MethodsUSPTOApplication 19666098
  • PendingNovel MethodsUSPTOApplication 19304556
  • PendingNovel MethodsUSPTOApplication 19317044
Show all 40 patent records

Recent research by its founders

  • Cyclic nucleotide phosphodiesterases as drug targets202528 cites
  • 319. Discovery and Development of ITI-1549: A Novel Serotonin 5-HT2A Agonist, Non-Hallucinogenic Neuroplastogen, for the Treatment of Neuropsychiatric Disorders20250 cites
  • Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders20243 cites

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .